240 related articles for article (PubMed ID: 22911653)
1. Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: "minimal change PBC"?
Khan FM; Komarla AR; Mendoza PG; Bodenheimer HC; Theise ND
Hepatology; 2013 Feb; 57(2):700-7. PubMed ID: 22911653
[TBL] [Abstract][Full Text] [Related]
2. Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis.
Kakuda Y; Harada K; Nakanuma Y
J Clin Pathol; 2015 Feb; 68(2):141-7. PubMed ID: 25430494
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of langerhans cell infiltrate by CD1a immunostain in liver biopsy for the diagnosis of primary biliary cirrhosis.
Graham RP; Smyrk TC; Zhang L
Am J Surg Pathol; 2012 May; 36(5):732-6. PubMed ID: 22498823
[TBL] [Abstract][Full Text] [Related]
4. Portal tract eosinophils and hepatocyte cytokeratin 7 immunoreactivity helps distinguish early-stage, mildly active primary biliary cirrhosis and autoimmune hepatitis.
Goldstein NS; Soman A; Gordon SC
Am J Clin Pathol; 2001 Dec; 116(6):846-53. PubMed ID: 11764073
[TBL] [Abstract][Full Text] [Related]
5. Destruction of canals of Hering in primary biliary cirrhosis.
Saxena R; Hytiroglou P; Thung SN; Theise ND
Hum Pathol; 2002 Oct; 33(10):983-8. PubMed ID: 12395370
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
7. Immunostaining of plasma cells in primary biliary cirrhosis.
Daniels JA; Torbenson M; Anders RA; Boitnott JK
Am J Clin Pathol; 2009 Feb; 131(2):243-9. PubMed ID: 19141384
[TBL] [Abstract][Full Text] [Related]
8. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
[TBL] [Abstract][Full Text] [Related]
9. The detection of bile ducts in liver biopsies by cytokeratin 7.
Rubio CA
In Vivo; 1998; 12(2):183-6. PubMed ID: 9627800
[TBL] [Abstract][Full Text] [Related]
10. Early histopathologic changes in primary biliary cholangitis: does 'minimal change' primary biliary cholangitis exist? A pathologist's view.
Chatzipantelis P; Giatromanolaki A
Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):e7-e12. PubMed ID: 32804848
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome.
Suzuki Y; Arase Y; Ikeda K; Saitoh S; Tsubota A; Suzuki F; Kobayashi M; Akuta N; Someya T; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2004 Jun; 19(6):699-706. PubMed ID: 15151627
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitis-primary biliary cirrhosis overlap syndrome.
Lee H; Stapp RT; Ormsby AH; Shah VV
Am J Clin Pathol; 2010 Mar; 133(3):430-7. PubMed ID: 20154281
[TBL] [Abstract][Full Text] [Related]
13. Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis.
Haruta I; Hashimoto E; Kato Y; Kikuchi K; Kato H; Yagi J; Uchiyama T; Kobayash M; Shiratori K
Autoimmunity; 2006 Mar; 39(2):129-35. PubMed ID: 16698669
[TBL] [Abstract][Full Text] [Related]
14. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome.
Muratori P; Granito A; Pappas G; Pendino GM; Quarneti C; Cicola R; Menichella R; Ferri S; Cassani F; Bianchi FB; Lenzi M; Muratori L
Am J Gastroenterol; 2009 Jun; 104(6):1420-5. PubMed ID: 19491855
[TBL] [Abstract][Full Text] [Related]
15. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome.
Twaddell WS; Lefkowitch J; Berk PD
Semin Liver Dis; 2008 Feb; 28(1):128-34. PubMed ID: 18293283
[TBL] [Abstract][Full Text] [Related]
16. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis.
Sakisaka S; Kawaguchi T; Taniguchi E; Hanada S; Sasatomi K; Koga H; Harada M; Kimura R; Sata M; Sawada N; Mori M; Todo S; Kurohiji T
Hepatology; 2001 Jun; 33(6):1460-8. PubMed ID: 11391535
[TBL] [Abstract][Full Text] [Related]
17. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis.
Van de Water J; Gerson LB; Ferrell LD; Lake JR; Coppel RL; Batts KP; Wiesner RH; Gershwin ME
Hepatology; 1996 Nov; 24(5):1079-84. PubMed ID: 8903379
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and pathological characterization of the overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis].
Zhu GJ; Chen S; Mao Q; Wang YM
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):6-8. PubMed ID: 15670481
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.
Yamazaki K; Suzuki K; Nakamura A; Sato S; Lindor KD; Batts KP; Tarara JE; Kephart GM; Kita H; Gleich GJ
Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
